BioStock: Iconovo's high aiming business goals

Last week, Iconovo announced its financial targets for 2026. In five years, the company expects to have ten projects in development and five launched inhalation products that generate royalties. In addition, the goal is to enter into 1 – 3 new customer agreements per year on the way there. All in all, this is expected to generate sales of 200 million SEK and an operating profit of 100 million SEK in 2026. Iconovo also sees two potential upsides: royalty revenue from innovative inhalation products as well as from royalty revenue from generic Symbicort in the US.

Read the full article at biostock.se:

https://www.biostock.se/en/iconovos-high-aiming-business-goals/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se